EpiSante Biomedical | LiverRP-Prognosis of liver Cancer Resection | DNA methylation analysis | cancer management
Products and Services
- Testing Service
- 2nd Generation of Liver Cancer Early Screening-MPMEpiSante Biomedical - 2nd Generation of Liver Cancer Early Screening-LiverES | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy
- Prognosis and Monitoring of Liver Cancer Ablation-LiverAMEpiSante Biomedical - Prognosis and Monitoring of Liver Cancer Ablation-LiverAM | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy
- CancerMeth-Cancer Gene Methylation TestEpiSante Biomedical - CancerMeth-Cancer Gene Methylation Test | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy
- LiverMeth-Liver Cancer Gene Methylation TestEpiSante Biomedical - LiverMeth-Liver Cancer Gene Methylation Test | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy
- Global DNA Methylation TestEpiSante Biomedical - Global DNA Methylation Test | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy
- MethClock-Biological Age Anti-aging TestEpiSante Biomedical - Global DNA Methylation Test | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy
- Establishment and Consulting of LDTs LabEpiSante Biomedical - Establishment and Consulting of LDTs Lab | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy
- Reagents and KitsEpiSante Biomedical - Reagents and Kits | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy
- Customized ServiceEpiSante Biomedical - Customized Service | DNA methylation | methylation, cancer testing, liver cancer, liver testing, liquid biopsy, liver prognosis, liver ablation, liver resection, immunotherapy, cell therapy
LiverRP-Prognosis of liver Cancer Resection
Liver cancer resection is the first choice for patients in the early stages of liver cancer and is one of the few methods that can cure liver cancer. However, the long-term survival rate following liver cancer resection is still not satisfactory, due to its high recurrence rate of up to 70% within five years. LiverRP can assist doctors in formulating postoperative treatment strategies, such as closely monitoring patients with a poor prognosis or administering preventive treatment, to increase survival rates.
Our Advantages
World-leading
LiverRP is the world's first product that uses methylation markers as a prognostic tool for liver cancer resection.
Precise
Compared to current biochemical markers and clinical pathological evaluations, LiverRP can serve as a more precise postoperative assessment tool.
Convenient
LiverRP uses tissue samples removed during surgery for testing, eliminating the need for additional sampling.
Innovative
LiverRP uses qMSP technology, with an exclusive patented gene panel, to improve precision and testing throughput.
Who needs the testing?
Patients treated with liver resection
Clinical Performance of LiverRP
Clinical Performance of LiverRP - AUC
AUC (Area Under Curve) is the area under the ROC curve, representing the ability to predict cancer.
AUC=1 means both sensitivity and specificity are 100%. AUC = 0.5 represents no discrimination; AUC between 0.6 and 0.7 is acceptable discrimination; AUC between 0.7 and 0.8 has excellent discrimination; AUC between 0.9 and 1 represents excellent discrimination.
Clinical Performance of LiverRP- Sensitivity
Sensitivity, also known as the true positive rate, refers to the proportion of actual early recurrence of liver cancer samples that are detected and diagnosed as early recurrence of liver cancer.
Clinical Performance of LiverRP- Specificity
Specificity, also known as the true negative rate, refers to the proportion of actual non-early recurrence of liver cancer samples that are judged to be non-early recurrence of liver cancer.
Clinical Performance of LiverRP-prediction of 5-year survival
According to the results of the LiverRP test, the five-year survival rate for liver cancer patients judged to be at low risk is 91.3%, while the fiveyear survival rate for highrisk patients is 43.6%. The results show that LiverRP can effectively assess high-risk patients after surgery and those with poor prognosis.